Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Recce Pharmaceuticals Ltd (ASX: RCE) is a global biotechnology company engaged in the development and commercialisation of a new class of antibiotics. It operates in only one business segment, being research and development of pharmaceutical drugs.
Based in Australia, the company also has operations in the United Kingdom, and the United States. Recce offers antibiotic drugs to treat diseases caused by various bacterias including sepsis, Helicobacter pylori, Escherichia coli, Pseudomonas aeruginosa, and others.
With COVID-19 in the backdrop of 2020, the Recce share price has been pushing higher in the last 12 months.
|13 Oct 2021||$0.99||$0.07||7.61%||82,757||$0.95||$0.99||$0.91|
|12 Oct 2021||$0.92||$0.01||1.09%||41,172||$0.91||$0.92||$0.90|
|08 Oct 2021||$0.92||$-0.02||-2.15%||16,751||$0.94||$0.94||$0.92|
|07 Oct 2021||$0.93||$0.00||0.00%||176,270||$0.93||$0.93||$0.88|
|06 Oct 2021||$0.93||$-0.02||-2.09%||60,367||$0.95||$0.95||$0.92|
|05 Oct 2021||$0.96||$-0.02||-2.06%||90,929||$0.97||$0.97||$0.92|
|04 Oct 2021||$0.97||$-0.02||-2.02%||125,810||$0.99||$1.01||$0.96|
|01 Oct 2021||$0.99||$0.01||1.02%||61,001||$0.98||$1.00||$0.97|
|30 Sep 2021||$0.98||$0.02||2.08%||425,052||$0.96||$1.02||$0.96|
|29 Sep 2021||$0.96||$-0.01||-1.04%||2,835||$0.97||$0.97||$0.96|
|28 Sep 2021||$0.97||$-0.01||-1.03%||155,670||$0.97||$0.97||$0.94|
|27 Sep 2021||$0.97||$0.01||1.04%||45,065||$0.96||$0.97||$0.96|
|24 Sep 2021||$0.96||$0.00||0.00%||80,381||$0.96||$0.97||$0.94|
|23 Sep 2021||$0.96||$0.05||5.49%||161,087||$0.91||$0.96||$0.87|
|22 Sep 2021||$0.91||$0.01||1.10%||492,290||$0.89||$0.92||$0.87|
|21 Sep 2021||$0.91||$-0.02||-2.17%||97,575||$0.92||$0.92||$0.87|
|20 Sep 2021||$0.92||$-0.03||-3.14%||192,419||$0.96||$0.96||$0.89|
|17 Sep 2021||$0.96||$-0.04||-4.04%||84,189||$0.98||$0.98||$0.95|
|16 Sep 2021||$0.99||$0.01||1.02%||325,443||$0.97||$1.00||$0.93|
|15 Sep 2021||$0.98||$-0.01||-1.01%||71,592||$0.96||$0.98||$0.93|
|14 Sep 2021||$0.99||$-0.02||-1.97%||153,121||$1.02||$1.02||$0.95|
|21 Jun 2021||Michele Dilizia||Sell||175||$178,238|| |
|16 Jun 2021||James Graham||Buy||47||$50,003|| |
|22 Feb 2021||Alan Dunton||Issued||1||$1,158,750|| |
Issue of options.
|22 Feb 2021||Michele Dilizia||Issued||1||$1,545,000|| |
Issue of options.
|22 Feb 2021||John Prendergast||Issued||2||$2,240,250|| |
Issue of options.
|22 Feb 2021||Justin Ward||Issued||600||$618,000|| |
Issue of options.
|22 Feb 2021||James Graham||Issued||2||$2,317,500|| |
Issue of options.
|04 Dec 2020||Alan Dunton||Issued||60||$73,200|| |
Director remuneration. As per announcement on 11/12/2020.
|Mr James Hamilton Bray Graham||Executive DirectorChief Executive Officer||Jun 2015|| |
Mr Graham is Chief Executive Officer and Executive Director of the Company. Mr Graham has a background in marketing, business development and commercialisation of early stage technology with global potential. Mr Graham continues to work closely with the growth and direction of Company, routinely investing alongside shareholders in capital rounds to date.
|Dr Alan William Dunton||Non-Executive Director||Jul 2020|| |
Dr Dunton has held leadership positions at various biotechnology and pharmaceutical companies including serving as president and chief executive officer at Panacos Pharmaceuticals, Inc., Metaphore Pharmaceuticals, Inc., and chief operating officer at Emisphere Technologies, Inc. Dr Dunton served in several positions at Johnson and Johnson including president and managing director at the Janssen Research Foundation where he was responsible for leading over 2,000 professionals worldwide and prior to this as vice president of global clinical research and development at the R.W. Johnson Pharmaceutical Research Institute. In 1987, he was awarded The Nellie Westerman Prize from the American Federation for Clinical Research (AFCR) for his work in medical ethics. Directorships held by him in other listed entities during the last three years are Palatin Technologies, Inc. (NYSE: PTN) Oragenics, Inc. (NYSE: OGEN) CorMedix, Inc. (NYSE: GRMD) Regeneus Ltd (ASX: RGS)
|Ms Michele Keryn Dilizia||Executive Director||Jun 2015|| |
Ms Dilizia is a Medical Scientist with specialisation in medical microbiology. Previously, she had a executive career in public relations and marketing for a leading retail chain. Ms Dilizia was a market research consultant, which included marketing development of health-care and pharmaceutical products.
|Dr John Prendergast||Non-Executive DirectorNon-Executive Chairman||Apr 2018|| |
Dr Prendergast is currently Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN), a US biotechnology company capitalised at over US$260m, developing therapeutics for diseases with significant unmet medical need; and Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX). Dr Prendergast held previous US biotechnology Board Positions, most notably Lead Director of MediciNova, Inc. valued at over US$470m (Nasdaq: MNOV) and Osaka Securities Exchange (#4875) and Co-founder/ Lead Director of Avigen, Inc, which was acquired by MediciNova in 2009 for US$37m. Prior to a career in commercialising pharmaceutical technologies, Dr Prendergast was Managing Director of Paramount Capital Investments and The Castle Group. Dr Prendergast has also served as a member of the Advisory Board for the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute. Directorships held in other listed entities during the last three years by him are Palatin Technologies, Inc. (NYSE: PTN) Heat Biologics, Inc. (NASDAQ: HTBX)
|Dr Justin Ward||Executive Director||Jul 2019|| |
Dr Ward is a chemist with specialisation in pharmaceutical quality management and product development. Before Recce Pharmaceuticals, he held a technical speciality and special project leadership role with Pfizer Pharmaceuticals, involving providing data for the regulatory submissions to the FDA and TGA. After Pfizer, he was the Laboratory Manager for Solbec, involving, again as presently, drug specifications and pharmaceutical trials for the ASX-Listed company
|Mr Alistair McKeough||Company Secretary||Nov 2017|| |
|Justin Reynolds||Chief Financial Officer|| |
|Alistair McKeough||Company Secretary|| |
|Daniel Astudillo||Head of Marketing|| |
|Arthur Kollaras||Principal Engineer & Head of Manufacturing|| |
|Graham Melrose and Olga Melrose||38,428,311||22.11%|
|LDU Pty Ltd||6,418,237||3.69%|
|HSBC Custody Nominees (Australia) Limited||6,046,316||3.48%|
|Mr James Graham||6,031,932||3.47%|
|Acuity Capital Investment Mangement Pty Ltd <Acuity Capital Holdings A/C>||4,500,000||2.59%|
|Ms Michele Keryn Dilizia||3,543,485||2.04%|
|Acewood Investments Pty Ltd <Chivers Super Fund A/C>||3,184,616||1.83%|
|BNP Paribas Noms Pty Ltd <DRP>||2,329,590||1.34%|
|Querion Pty Ltd||2,100,000||1.21%|
|Pejay Pty Limited||1,860,000||1.07%|
|Mr John James Liddelow <John Liddelow A/C>||1,525,000||0.88%|
|Mark David Swinn||1,217,002||0.70%|
|Shortis Natural Therapies Pty Limited <Shortis Family A/C>||1,200,000||0.69%|
|Mr Nikolai Shirobokov & Mrs Svetlana Shirobokov||1,102,974||0.63%|
|Citicorp Nominees Pty Limited||1,093,709||0.63%|
|Mccray Investments Pty Ltd <Mccray Fam Sf A/C>||1,002,500||0.58%|
|Mr Robert Cerny & Mrs Zaphiero John Cerny <Parez Super Fund A/C>||1,000,000||0.58%|
|Mr Leslie John Field & Mrs Eve Field||938,504||0.54%|
|BNP Paribas Nominees Pty Ltd ACF Clearstream||920,439||0.53%|